MXPA04005077A - Derivados de benzotiazol. - Google Patents
Derivados de benzotiazol.Info
- Publication number
- MXPA04005077A MXPA04005077A MXPA04005077A MXPA04005077A MXPA04005077A MX PA04005077 A MXPA04005077 A MX PA04005077A MX PA04005077 A MXPA04005077 A MX PA04005077A MX PA04005077 A MXPA04005077 A MX PA04005077A MX PA04005077 A MXPA04005077 A MX PA04005077A
- Authority
- MX
- Mexico
- Prior art keywords
- lower alkyl
- compounds
- receptor
- hydrogen
- general formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se refiere a compuestos de la formula general (I),(ver formula I),en donde R1 es hidrogeno o alquilo inferior; R2 es alquilo inferior, -(CH2)n-O-alquilo inferior, -ciclo-alquilo de 3 a 6 atomos de carbono o -(CH2)n-NR??2; R?? es hidrogeno, alquilo inferior o -(CH2)n-O-alquilo inferior, independientemente entre si para R??2, o R??2 puede formar junto con el atomo de N un anillo de pirrolidina, n es 1, 2 o 3; y a sus sales de adicion acida farmaceuticamente aceptables. Se ha descubierto sorprendendentemente que los compuestos de formula general I son ligandos del receptor de la denosina. Especificamente, los compuestos de la presente invencion tienen una buena afinidad para el receptor A2A y por lo tanto son utiles en el tratamiento de enfermedades, relacionadas con este receptor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01128338 | 2001-11-29 | ||
PCT/EP2002/013046 WO2003045386A1 (en) | 2001-11-29 | 2002-11-21 | Benzothiazole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04005077A true MXPA04005077A (es) | 2004-08-19 |
Family
ID=8179392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04005077A MXPA04005077A (es) | 2001-11-29 | 2002-11-21 | Derivados de benzotiazol. |
Country Status (20)
Country | Link |
---|---|
US (1) | US6624163B2 (es) |
EP (1) | EP1450797B1 (es) |
JP (1) | JP4146799B2 (es) |
KR (1) | KR100581704B1 (es) |
CN (1) | CN1304383C (es) |
AR (1) | AR037457A1 (es) |
AT (1) | ATE330603T1 (es) |
AU (1) | AU2002365506B2 (es) |
BR (1) | BR0214488A (es) |
CA (1) | CA2468311C (es) |
DE (1) | DE60212694T2 (es) |
ES (1) | ES2266608T3 (es) |
MX (1) | MXPA04005077A (es) |
PA (1) | PA8558701A1 (es) |
PE (1) | PE20030821A1 (es) |
PL (1) | PL373947A1 (es) |
RU (1) | RU2301232C2 (es) |
TW (1) | TW200408395A (es) |
UY (1) | UY27559A1 (es) |
WO (1) | WO2003045386A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1638556B1 (en) | 2003-06-20 | 2008-04-02 | F. Hoffmann-La Roche Ag | 2-aminobenzothiazoles as cb1 receptor inverse agonists |
KR20060058132A (ko) | 2003-09-19 | 2006-05-29 | 에프. 호프만-라 로슈 아게 | 아데노신 수용체 리간드로서의 싸이아졸로피리딘 유도체 |
TW200524887A (en) * | 2003-10-27 | 2005-08-01 | Lundbeck & Co As H | N-thiazol-2-yl-benzamide derivatives |
EP1677791A4 (en) | 2003-10-31 | 2007-08-15 | Takeda Pharmaceutical | NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS |
CA2551171C (en) * | 2003-12-23 | 2012-07-10 | Bio-Medisinsk Innovasjon As | Modulators of peripheral 5-ht receptors |
CA2574180A1 (en) | 2004-07-22 | 2006-01-26 | F. Hoffmann-La Roche Ag | Substituted benzothiazoles |
AU2005263500B2 (en) * | 2004-07-22 | 2011-02-24 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
AU2005287729A1 (en) | 2004-09-22 | 2006-03-30 | H. Lundbeck A/S | 2-acylaminothiazole derivatives |
US7674912B2 (en) | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
CN111205244B (zh) * | 2018-11-22 | 2023-08-18 | 上海科技大学 | 噻唑并环类化合物、其制备方法、中间体和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0113219B1 (en) | 1982-12-21 | 1987-11-19 | Johnsen & Jorgensen (Plastics) Limited | Dispensing container |
FI91859C (fi) | 1987-06-17 | 1994-08-25 | Eisai Co Ltd | Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi |
IL90337A0 (en) | 1988-05-24 | 1989-12-15 | Pfizer | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
KR0185225B1 (ko) * | 1992-05-21 | 1999-05-15 | 오오쓰까 아끼히꼬 | 포스폰산 디에스테르 유도체 |
KR100571161B1 (ko) | 2000-06-21 | 2006-04-17 | 에프. 호프만-라 로슈 아게 | 벤조티아졸 유도체 |
-
2002
- 2002-11-15 US US10/295,500 patent/US6624163B2/en not_active Expired - Fee Related
- 2002-11-21 ES ES02790418T patent/ES2266608T3/es not_active Expired - Lifetime
- 2002-11-21 WO PCT/EP2002/013046 patent/WO2003045386A1/en active IP Right Grant
- 2002-11-21 AU AU2002365506A patent/AU2002365506B2/en not_active Ceased
- 2002-11-21 DE DE60212694T patent/DE60212694T2/de not_active Expired - Lifetime
- 2002-11-21 MX MXPA04005077A patent/MXPA04005077A/es active IP Right Grant
- 2002-11-21 BR BR0214488-3A patent/BR0214488A/pt not_active Application Discontinuation
- 2002-11-21 RU RU2004119985/04A patent/RU2301232C2/ru not_active IP Right Cessation
- 2002-11-21 EP EP02790418A patent/EP1450797B1/en not_active Expired - Lifetime
- 2002-11-21 AT AT02790418T patent/ATE330603T1/de active
- 2002-11-21 JP JP2003546888A patent/JP4146799B2/ja not_active Expired - Fee Related
- 2002-11-21 PL PL02373947A patent/PL373947A1/xx not_active Application Discontinuation
- 2002-11-21 KR KR1020047007915A patent/KR100581704B1/ko not_active IP Right Cessation
- 2002-11-21 CA CA2468311A patent/CA2468311C/en not_active Expired - Fee Related
- 2002-11-21 CN CNB028236939A patent/CN1304383C/zh not_active Expired - Fee Related
- 2002-11-25 PE PE2002001131A patent/PE20030821A1/es not_active Application Discontinuation
- 2002-11-25 TW TW091134237A patent/TW200408395A/zh unknown
- 2002-11-26 PA PA20028558701A patent/PA8558701A1/es unknown
- 2002-11-28 UY UY27559A patent/UY27559A1/es not_active Application Discontinuation
- 2002-11-28 AR ARP020104580A patent/AR037457A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20040062967A (ko) | 2004-07-09 |
JP2005518363A (ja) | 2005-06-23 |
EP1450797B1 (en) | 2006-06-21 |
AU2002365506A1 (en) | 2003-06-10 |
BR0214488A (pt) | 2004-10-19 |
US20030134855A1 (en) | 2003-07-17 |
CA2468311C (en) | 2011-03-15 |
KR100581704B1 (ko) | 2006-05-22 |
CN1304383C (zh) | 2007-03-14 |
PA8558701A1 (es) | 2003-09-05 |
AR037457A1 (es) | 2004-11-10 |
DE60212694T2 (de) | 2007-06-28 |
PE20030821A1 (es) | 2003-10-04 |
US6624163B2 (en) | 2003-09-23 |
JP4146799B2 (ja) | 2008-09-10 |
RU2004119985A (ru) | 2006-01-10 |
CN1596112A (zh) | 2005-03-16 |
CA2468311A1 (en) | 2003-06-05 |
EP1450797A1 (en) | 2004-09-01 |
WO2003045386A1 (en) | 2003-06-05 |
RU2301232C2 (ru) | 2007-06-20 |
ES2266608T3 (es) | 2007-03-01 |
TW200408395A (en) | 2004-06-01 |
DE60212694D1 (de) | 2006-08-03 |
UY27559A1 (es) | 2003-05-30 |
PL373947A1 (en) | 2005-09-19 |
AU2002365506B2 (en) | 2006-08-10 |
ATE330603T1 (de) | 2006-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU91761I2 (fr) | Vernakalant et ses dérivés pharmaceutiquement acceptables et en particulier son sel d'hydrochlorure (BRINAVESS®) | |
MY136270A (en) | Processes and intermediates for preparing anti-cancer compounds | |
NZ514873A (en) | 4,5,6,7-tetrahydroindazole derivatives as antitumor agents | |
MY135841A (en) | Novel benzodioxoles | |
TWI255807B (en) | Therapeutic agents | |
MY138352A (en) | Benzothiazole derivatives | |
DE69923849D1 (de) | Quinolin-2-on-derivate verwendbar als antikrebsmittel | |
MXPA02012034A (es) | Derivados de tiofeno utiles como agentes anticancerosos. | |
SE0104332D0 (sv) | Therapeutic agents | |
RS20050469A (en) | Pyrrolopyrimidine derivatives | |
EP1035123A4 (en) | NEW HETEROCYCLIC COMPOUNDS | |
WO2002080846A3 (en) | Epothilone derivatives and methods for making and using the same | |
MY139357A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
PL373414A1 (en) | 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands | |
JO2321B1 (en) | 4-phenyl-pyridine derivatives | |
ZA200305116B (en) | Purine derivatives as purinergic receptor antagonists. | |
TW200619212A (en) | Morpholine derivatives | |
MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
MXPA04001250A (es) | Derivados de arilsulfonilo con afinidad receptora de 5-hidroxitriptamina6 (5-ht6). | |
NZ528997A (en) | Sulfonamides | |
MXPA03011466A (es) | Macrociclos utiles en tratamiento de enfermedades de alzheimer. | |
MXPA04005077A (es) | Derivados de benzotiazol. | |
IL150817A0 (en) | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | |
BG104983A (en) | Aryl fused azapolycyclic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |